Studies of the long-term course of opioid use disorder (OUD) underscore how the condition is exacerbated by factors such as interactions with the criminal justice system, limited access to medications to treat OUD, chronic unemployment and conditions of poverty, physical/psychological trauma and related mental illness, social isolation, and poor social support. Developments in pharmacotherapies for OUD and innovative means of administration have yielded important advances in effective medication-based treatments, yet social and political structures remain as obstacles in some regions of the United States and other parts of the world affected by OUD. Changes in perceptions about OUD as a chronic brain disease and about the effectiveness of pharmacotherapies for OUD indicate a public health approach may slowly supersede the criminal justice approach to addressing OUD. This chapter provides an overview of OUD problems as they have emerged and as they are societally and clinically addressed, emphasizing the management and treatment of OUD with effective use of available pharmacotherapies and within environments that are supportive of recovery.
- Opioid use disorder
- Heroin use disorder
- Natural history
- Prospective cohort studies
- Life course
- Long-term recovery
This is a preview of subscription content, access via your institution.
Hedegaard H, Warner M, Miniño AM. Drug overdose deaths in the United States, 1999-2016, NCHS data brief, no 294. Hyattsville: National Center for Health Statistics; 2017.
Case A, Deaton A. Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. Proc Natl Acad Sci U S A. 2015;112(49):15078–83.
Kochanek KD, Murphy SL, Xu JQ, Arias E. Mortality in the United States, 2016, NCHS data brief, no 293. Hyattsville: National Center for Health Statistics; 2017.
U.S. Department of Health and Human Services (HHS). Facing addiction in America: the Surgeon General’s report on alcohol, drugs, and health, vol. 17. Washington, DC: HHS; 2016. p. 6.
Rudder M, Tsao L, Jack HE. Shared responsibility: Massachusetts legislators, physicians, and an act relative to substance use treatment, education, and prevention. AMA J Ethics. 2016;18(9):950–9.
D’Onofrio G, Chawarski MC, O’Connor PG, Pantalon MV, Busch SH, Owens PH, et al. Emergency department-initiated buprenorphine for opioid dependence with continuation in primary care: outcomes during and after intervention. J Gen Intern Med. 2017;32(6):660–6.
Martin A, Mitchell A, Wakeman S, White B, Raja A. Emergency department treatment of opioid addiction: an opportunity to lead. Acad Emerg Med. 2018;25(5):601–4.
Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA Jr, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016;374(13):1232–42.
Farabee D, Hillhouse M, Condon T, McCrady B, McCollister K, Ling W. Injectable pharmacotherapy for opioid use disorders (IPOD). Contemp Clin Trials. 2016;49:70–7.
Hser YI, Anglin MD, Grella C, Longshore D, Prendergast ML. Drug treatment careers: a conceptual framework and existing research findings. J Subst Abus Treat. 1997;14(6):543–58.
Hser YI. Predicting long-term stable recovery from heroin addiction: findings from a 33-year follow-up study. J Addict Dis. 2007;26(1):51–60.
Hser YI, Evans E, Grella C, Ling W, Anglin D. Long-term course of opioid addiction. Harv Rev Psychiatry. 2015;23(2):76–89.
Hser YI, Hoffman V, Grella CE, Anglin MD. A 33-year followup of narcotics addicts. Arch Gen Psychiatry. 2001;58(5):503–8.
Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011;106(1):32–51.
Hser YI, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Zhu Y, et al. High mortality among patients with opioid use disorder in a large healthcare system. J Addict Med. 2017;11(4):315–9.
Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207.
Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31(3):207–25.
Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction. 2009;104(7):1193–200.
Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11:1–171, iii–iv.
Hser YI, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, et al. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction. 2016;111(4):695–705.
Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;2:CD002207.
Evans E, Li L, Min J, Huang D, Urada D, Liu L, et al. Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10. Addiction. 2015;110(6):996–1005.
Thomas CP, Fullerton CA, Kim M, Montejano L, Lyman DR, Dougherty RH, et al. Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv. 2014;65(2):158–70.
Woody G, Bruce D, Korthuis PT, Chhatre S, Hillhouse M, Jacobs P, et al. HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. J Acquir Immune Defic Syndr. 2014;66(3):288–93.
Chi FW, Weisner C, Grella CE, Hser YI, Moore C, Mertens J. Does age at first treatment episode make a difference in outcomes over 11 years? J Subst Abus Treat. 2014;46(4):482–90.
Evans E, Li L, Grella C, Brecht ML, Hser YI. Developmental timing of first drug treatment and 10-year patterns of drug use. J Subst Abus Treat. 2013;44(3):271–9.
Darke S, Ross J, Mills KL, Williamson A, Havard A, Teesson M. Patterns of sustained heroin abstinence amongst long-term, dependent heroin users: 36 months findings from the Australian Treatment Outcome Study (ATOS). Addict Behav. 2007;32(9):1897–906.
Skinner ML, Haggerty KP, Fleming CB, Catalano RF, Gainey RR. Opiate-addicted parents in methadone treatment: long-term recovery, health, and family relationships. J Addict Dis. 2010;30(1):17–26.
Krebs E, Min JE, Evans E, Li L, Liu L, Huang D, et al. Estimating state transitions for opioid use disorders. Med Decis Mak. 2017;37(5):483–97.
Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309–18.
Burns L, Gisev N, Larney S, Dobbins T, Gibson A, Kimber J, et al. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia. Addiction. 2015;110(4):646–55.
Proctor SL, Copeland AL, Kopak AM, Herschman PL, Polukhina N. A naturalistic comparison of the effectiveness of methadone and two sublingual formulations of buprenorphine on maintenance treatment outcomes: findings from a retrospective multisite study. Exp Clin Psychopharmacol. 2014;22(5):424–33.
Evans E, Yoo C, Huang D, Hser YI. Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 5 years: results from a multisite randomized trial of patients with opioid use disorder. In review 2019.
Evans E, Grella C. Gender and mental health comorbidity among adults with opioid use disorders: results from the 2012–2013 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC-III). Oral presentation, college on problems of drug dependence annual meeting June 2018, San Diego, CA.
Evans EA, Grella CE, Washington DL, Upchurch DM. Gender and race/ethnic differences in the persistence of alcohol, drug, and poly-substance use disorders. Drug Alcohol Depend. 2017;174:128–36.
Scherbaum N, Specka M. Factors influencing the course of opiate addiction. Int J Methods Psychiatr Res. 2008;17(S1):S39–44.
Darke S. Pathways to heroin dependence: time to re-appraise self-medication. Addiction. 2013;108(4):659–67.
Hemsing N, Greaves L, Poole N, Schmidt R. Misuse of prescription opioid medication among women: a scoping review. Pain Res Manag. 2016;2016:1754195.
Edlund MJ, Steffick D, Hudson T, Harris KM, Sullivan M. Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain. 2007;129(3):355–62.
Grella CE, Lovinger K. Gender differences in physical and mental health outcomes among an aging cohort of individuals with a history of heroin dependence. Addict Behav. 2012;37(3):306–12.
Lalic S, Gisev N, Bell JS, Korhonen MJ, Ilomäki J. Predictors of persistent prescription opioid analgesic use among people without cancer in Australia. Br J Clin Pharmacol. 2018;84(6):1267–78.
Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain-United States, 2016. JAMA. 2016;315(15):1624–45.
Hser YI, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Huang D. Chronic pain among patients with opioid use disorder: results from electronic health records data. J Subst Abus Treat. 2017;77:26–30.
Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159(9):592–600.
Bukten A, Stavseth MR, Skurtveit S, Tverdal A, Strang J, Clausen T. High risk of overdose death following release from prison: variations in mortality during a 15-year observation period. Addiction. 2017;112(8):1432–9.
Nosyk B, Anglin MD, Brecht ML, Lima VD, Hser YI. Characterizing durations of heroin abstinence in the California civil addict program: results from a 33-year observational cohort study. Am J Epidemiol. 2013;177(7):675–82.
Dasgupta N, Beletsky L, Ciccarone D. Opioid crisis: no easy fix to its social and economic determinants. Am J Public Health. 2018;108(2):182–6.
Wiessing L, Ferri M, Darke S, Simon R, Griffiths P. Large variation in measures used to assess outcomes of opioid dependence treatment: a systematic review of longitudinal observational studies. Drug Alcohol Rev. 2018;37(S1):S323–38.
Hser YI, Huang D, Saxon AJ, Woody G, Moskowitz AL, Matthews AG, et al. Distinctive trajectories of opioid use over an extended follow-up of patients in a multisite trial on buprenorphine+ naloxone and methadone. J Addict Med. 2017;11(1):63–9.
Zhu Y, Evans EA, Mooney LJ, Saxon AJ, Kelleghan A, Yoo C, Hser YI. Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial. J Neuroimmune Pharmacol. 2018;13(4):488–497.
Grella CE, Lovinger K. 30-year trajectories of heroin and other drug use among men and women sampled from methadone treatment in California. Drug Alcohol Depend. 2011;118(2–3):251–8.
Termorshuizen F, Krol A, Prins M, van Ameijden EJ. Long-term outcome of chronic drug use: the Amsterdam Cohort Study among drug users. Am J Epidemiol. 2005 Feb;161(3):271–9.
Wang L, Min JE, Krebs E, Evans E, Huang D, Liu L, et al. Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. Int J Drug Policy. 2017;49:32–40.
Institute of Medicine (US). Committee on Crossing the Quality Chasm: Adaptation to Mental Health and Addictive Disorders. Improving the quality of health care for mental and substance-use conditions. Washington, DC: National Academy Press; 2006.
Substance Abuse and Mental Health Services Administration. SAMHSA’s working definition of recovery: 10 guiding principles of recovery. Rockville: SAMHSA; 2012.
White WL. Recovery: its history and renaissance as an organizing construct concerning alcohol and other drug problems. Alcohol Treat Q. 2005;23(1):3–15.
White WL. Slaying the dragon: the history of addiction treatment and recovery in America. Bloomington: Chestnut Health Systems/Lighthouse Institute; 1998.
White WL. Pre-AA alcoholic mutual aid societies. Alcohol Treat Q. 2001;19(2):1–21.
Humphreys K. Circles of recovery: self-help organizations for addictions. Cambridge: Cambridge University Press; 2004.
Maddux JF, Desmond DP. Relapse and recovery in substance abuse careers. NIDA Res Monogr. 1986;72:49–72.
Laudet AB, White WL. Recovery capital as prospective predictor of sustained recovery, life satisfaction, and stress among former poly-substance users. Subst Use Misuse. 2008;43(1):27–54.
Sobell LC, Ellingstad TP, Sobell MB. Natural recovery from alcohol and drug problems: methodological review of the research with suggestions for future directions. Addiction. 2000;95(5):749–64.
Hanninen V, Koski-Jannes A. Narratives of recovery from addictive behaviours. Addiction. 1999;94(12):1837–48.
McIntosh J, McKeganey N. Addicts’ narratives of recovery from drug use: constructing a non-addict identity. Soc Sci Med. 2000;50(10):1501–10.
Vigilant LG. “I am still suffering:” the dilemma of multiple recoveries in the lives of methadone maintenance patients. Sociol Spectr. 2008;28(3):278–98.
Laudet AB. The road to recovery: where are we going and how do we get there? Empirically driven conclusions and future directions for service development and research. Subst Use Misuse. 2008;43(12–13):2001–20.
Kaskutas LA, Borkman TJ, Laudet A, Ritter LA, Witbrodt J, Subbaraman MS, et al. Elements that define recovery: the experiential perspective. J Stud Alcohol Drugs. 2014;75(6):999–1010.
Witbrodt J, Kaskutas LA, Grella CE. How do recovery definitions distinguish recovering individuals? Five typologies. Drug Alcohol Depend. 2015;148:109–17.
Betty Ford Institute Consensus Panel. What is recovery? A working definition from the Betty Ford Institute. J Subst Abus Treat. 2007;33(3):221–8.
McLellan T. What is recovery? Revisiting the Betty Ford Institute Consensus Panel definition: The Betty Ford Consensus Panel and Consultants. J Subst Abuse Treat. 2010;38(2):200–1.
Cloud W, Granfield R. Conceptualizing recovery capital: expansion of a theoretical construct. Subst Use Misuse. 2008;43(12–13):1971–86.
Granfield R, Cloud W. Social context and “natural recovery”: the role of social capital in the resolution of drug-associated problems. Subst Use Misuse. 2001;36(11):1543–70.
Dr. Evans is supported by the Greenwall Foundation, the National Institute on Drug Abuse (NIDA) UG3 DA0044830-02S1, and Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT) Grant No. 1H79T1081387-01. Dr. Hser is supported by NIDA R33DA045844 and UG1 DA013035.
Editors and Affiliations
Rights and permissions
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Evans, E.A., Hser, YI. (2019). The Natural History, Clinical Course, and Long-Term Recovery from Opioid Use Disorders. In: Kelly, J., Wakeman, S. (eds) Treating Opioid Addiction. Current Clinical Psychiatry. Humana, Cham. https://doi.org/10.1007/978-3-030-16257-3_9
Publisher Name: Humana, Cham
Print ISBN: 978-3-030-16256-6
Online ISBN: 978-3-030-16257-3
eBook Packages: MedicineMedicine (R0)